• SnoreStop® Extinguisher™
  • SnoreStop® Extinguisher™
  • SnoreStop® Extinguisher™

SnoreStop® Extinguisher™

Throat Spray - One Month Supply

SKU: 002
$19.99

About The Product


Ingredients


Reviews

SnoreStop Extinguisher is a fast-acting throat spray for snoring relief. Quick and easy to use.
Designed to help temporarily shrink swollen soft tissues that block the air passage in the back of the throat due to inflammation. 

Directions:
Shake before each use. At bedtime, spray once under the tongue and once in the back of the throat. We recommend repeated use of the product for 3 to 5 consecutive nights. For Maximum Results, you can use it in conjunction with SnoreStop NasoSpray. Eat, drink, and/or take any medicine at least 30 minutes prior to taking SnoreStop at bedtime.

* Individual results may vary. 

 

Ingredients:
  • Nux Vomica 4x: helps open contsricted pharynx
  • Belladonna 6x: helps decongest enlarged tonsils
  • Ephedra vulgaris 6x: helps relieve congestion  
  • Hydrastis Canadensis 6x: helps decongest swollen tongue
  • Kali Bichromicum 6x: helps relieve stuffy nose
  • Teucrium marum 6x: helps open air passages
  • Histaminum hydrochloricum 12x: natural antihistamine

Inactive ingredients: 75% water, 15% Alcohol (100 micro centiliters per spray) 9.9% Glycerin and 0.1% of Potassium sorbate. The glycerin is from vegetable source. 99.7% pure UPS Pharma grade, Natural, and GMO Free.

SnoreStop Extinguisher is prepared in accordance with the Homeopathic Pharmacopoeia of the United States (HPUS). All ingredients are recognized as an official collection of accepted drug ingredients by the Federal Food, Drug and Cosmetic Act and are manufactured in FDA-approved laboratories. Each natural ingredient comes either from plant, mineral or protein sources and is present only in harmless microscopic amounts in each dose. None of our ingredients contain any alkaloids, ephedrine or pseudo - ephedrine. SnoreStop is a natural homeopathic over-the-counter medicine regulated by the FDA.

Dilution Scale: 6X is equal to one part per million.

Claims follow requirement in CPG 400.400 and GLP of Sections 502 & 503 of the FDCA (“The Act”) and Part 201 Title 21 of the CFR to include Principle Display Panel of OTC Drug Labeling under 21 CFR 201.62. Uses and claims are taken from various authorized Materia Medica for references. They have not been reviewed by the Federal Drug and Administration.

 

vv